Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

February 27, 2026

Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702

January 22, 2026

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

January 8, 2026

Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

January 7, 2026

Asieris Pharmaceuticals Appoints Dr. Ningshu Liu as Chief Scientific Officer

January 3, 2026

Asieris’ APL-1202 Receives Health Canada’s Special Access Program Approval for Treatment of Free-Living Amoeba Infections

December 21, 2025

Asieris Announces Completion of CE Application Submission for Bladder Cancer Product APLD-2304, Received by Notified Body BSI Group

Technology Platform